- Plexus in a human body is responsible for the transmission of nerve signals to the muscles. Therefore, plexopathy is a condition wherein this process gets hindered generally due to nerve extension of compression. Plexopathy leads to weakness, sensory loss and loss of tendon reflexes
- The demand for Plexopathy Treatment is significantly driven by the increasing prevalence of diabetes, traumatic nerve injuries, and radiation-induced nerve damage, alongside the growing geriatric population, which is more susceptible to neurological disorders.
- North America is expected to dominate the Plexopathy Treatment market with a share of 38.7%, attributed to its advanced healthcare infrastructure, strong diagnostic capabilities, higher awareness levels, and the presence of leading neurological treatment centers and pharmaceutical companies.
- Asia-Pacific is expected to be the fastest-growing region in the Plexopathy Treatment market during the forecast period due to expanding healthcare access, increasing patient pool, supportive government initiatives, and growing investments in neurology research and rehabilitation.
- Medication segment is expected to dominate the market with a market share of 33.8% due to its wide availability, ease of administration, and primary role in managing pain and inflammation associated with plexopathy. Despite the rise of surgical interventions and physical therapy options, pharmacological treatment remains the frontline approach in both acute and chronic cases due to its immediate symptom relief and non-invasive nature
